References
- [cited Jul 2021. https://www.naaf.org/research
- Hunt N, McHale S. The psychological impact of alopecia. BMJ. 2005;331(7522):951–953.
- Sinclair RD. Alopecia and suicide of children. Med J Austr. 2014 Feb 17;200(3):145.
- Ikeda T. A new classification of alopecia areata. Dermatology. 1965;131(6):421–445.
- Messenger A, Sinclair R, Farrant P, et al. Acquired disorders of hair. In: editors, Griffiths C, Barker J, Bleiker T, et al. Rook’s textbook of dermatology. 9th ed. Oxford: Blackwell; 2016.
- Liu LY, Craiglow BG, Dai F, et al. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22–28.
- Lai VWY, Chen, G Gin, D, et al. Systemic treatments for alopecia areata: a systematic review. Austral J Dermatol. 2019;60(1): e1–e13. doi:https://doi.org/10.1111/ajd.12913 .
- Cranwell WC, Lai, VW, Photiou, L, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2): 163–170. doi:https://doi.org/10.1111/ajd.12941 .
- Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. Epub 2020 Sep 12. PMID: 32926985, J Am Acad Dermatol. 2021 Jun;84(6):1594–1601.
- Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. Epub 2020 Mar 9. PMID: 32165196, J Am Acad Dermatol. 2020 Jul;83(1):123–130.
- Hordinsky MK. Current treatments for alopecia areata. J Investig Dermatol Symp Proc. 2015;17(2):44–46.
- U.S Food & Drug Administration. Patient-focused drug development public meeting for alopecia areata [cited 2021 Jul]. 2017: https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm554443.htm.
- Divito SJ, Kupper TS. Inhibiting Janus kinases to treat alopecia areata. Nat Med. 2014;20(9):989.
- Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623–2629.
- O’Sullivan LA, Liongue C, Lewis RS, et al. Cytokine receptor signaling through the Jak-stat-Socs pathway in disease. Mol Immunol. 2007;44(10):2497–2506.
- Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–2990.
- Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014 Sep;20(9):1043–1049.
- de Medeiros A, Lambert J, Desmet E, . JAK3 as an emerging target for topical treatment of inflammatory skin diseaseas. PLoS One. 2016Oct6;11(10):e016408.
- Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study. Dermatology. 2019;235(2):130–136.
- Jabbari A, Dai Z, Xing L. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351–355.
- Jabbari A, Sansaricq F, Cerise J, et al. an open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Invest Dermatol. 2018;138(7):1539–1545.
- Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76(1):29–32.
- Ibrahim O, Bayart CB, Hogan S, et al. Treatment of Alopecia areata with Tofacitinib. JAMA Dermatol. 2017;153(6):600–602.
- Park H-S, Kim M-W, Lee JS, et al. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J Am Acad Dermatol. 2017;77(5):978–980.
- Kennedy CM, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776–e89776.
- Jerjen R, Meah N, Trindade de Carvalho L, et al. Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: a retrospective study. Pediatr Dermatol. 2021Jan;38(1):103–108. Epub 2020 Oct 25. PMID: 33099833.
- Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15). https://doi.org/10.1172/jci.insight.89790.
- Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019;80(2):566–568.
- Telliez JB, Dowty ME, Wang L, et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):3442–3451. [PubMed: 27791347].
- Thorarensen A, Dowty ME, Banker ME, et al., Design of a Janus Kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans. J Med Chem. 2017;60(5): 1971–1993.
- Suárez-Fariñas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clinical Immunol. 2015;136(5):1277–1287.
- Ito T, Ito N, Saatoff M, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008;128(5):1196–1206.
- Fensome A, Ambler CM, Arnold E, et al. Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018;61(19):8597–8612.
- [cited Jul 2021. https://clinicaltrials.gov/ProvidedDocs/68/NCT02974868/Prot_000.pdf
- Robinson M, Damjanov N, Stamenkovic B, et al. Efficacy and safety of PF-06651600 (Ritlecitinib), a novel JAK3/TEC inhibitor in patients with moderate to severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2020;10:1002.
- King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021 Mar 20;S0190-9622(21)00601–0.https://doi.org/10.1016/j.jaad.2021.03.050. Epub ahead of print. PMID: 33757798.
- Mendoza TR, Osei JS, Shi Q, et al. Development of the Alopecia Areata. Symptom Impact Scale. J investing Dermatol Symp Proc. 2013;16(1):S51–S52
- https://clinicaltrials.gov/ct2/show/NCT02974868?term=PF+06651600&cond=alopecia&draw=2&rank=4 [cited 2021 Aug].
- [cited Aug 2021]. https://clinicaltrials.gov/ct2/show/NCT03732807
- [cited Jul 2021]. https://clinicaltrials.gov/ct2/show/NCT04517864
- [cited Aug 2021]. https://clinicaltrials.gov/ct2/show/NCT04006457?term=ritlecitinib&cond=Alopecia+Areata&draw=2&rank=2
- [cited Aug 2021]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_breakthrough_therapy_designation_from_fda_for_pf_06651600_an_oral_jak3_inhibitor_for_the_treatment_of_patients_with_alopecia_areata
- De Vries LCS, Wildenberg ME, De Jonge WJ, et al. The future of janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis. 2017Jul1;11(7):885–893. Erratum in: J Crohns Colitis. 2017 Aug 1;11(8):1028.PMID: 28158411; PMCID: PMC5881740.
- Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016Dec;68(12):2857–2866. PMID: 27390150; PMCID: PMC5132065.
- O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii 111–5.
- Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018 Jul;27(12):2323–2335.
- Chen JC, Dai Z, Christiano AM. Regulatory network analysis defines unique drug mechanisms of action and facilitates patient-drug matching in alopecia areata clinical trials. Comput Struct Biotechnol J. 2021;19:4751–4758.
- Jerjen R, Meah N, Trindade de Carvalho L, et al. Folliculitis decalvans responsive to tofacitinib: a case series. Dermatol Ther. 2020Nov;33(6):e13968. Epub 2020 Aug 4. PMID: 32623800.
- Yang CC, Khanna T, Sallee B, et al. Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther. 2018Nov;31(6):e12656. Epub 2018 Sep 27. PMID: 30264512; PMCID: PMC6585740.
- Plante J, Eason C, Snyder A, et al. Tofacitinib in the treatment of lichen planopilaris: a retrospective review. J Am Acad Dermatol. 2020 Nov;835:1487–1489.
- [cited Jul 2021]. https://www.medchemexpress.com/PF-06651600.html